Hana Biosciences, Inc. (NASDAQ: HNAB), a South San Francisco, CA-based biopharmaceutical company, is focused on the acquisition, development and commercialization of novel products to strengthen the foundation of cancer care. The company is dedicated to creating value by accelerating the development of lead product candidates, building a best-in-class team, expanding its pipeline, and nurturing a unique company culture. For further information, visit the Company’s web site at www.hanabiosciences.com.
- 17 years ago
QualityStocks
Hana Biosciences, Inc. (NASDAQ: HNAB)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Signs Strategic Cooperation Agreement With BonV Aero To Expand Counter-UAS Presence In India
ParaZero Technologies (NASDAQ: PRZO) announced the signing of a strategic cooperation agreement with India-based BonV…
-
QualityStocksNewsBreaks – Black Hawk Acquisition Corporation (Nasdaq: BKHA) SPAC Target Vesicor Therapeutics Names Michael Tolentino CEO
Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR) announced that its proposed de-SPAC acquisition target, Vesicor Therapeutics Inc., has…
-
Renewal Fuels Inc. (RNWF) Discusses Ambitious Fusion Reactor Plan, Business Model and Strategy, on Stock2Me Podcast
The company aims to deliver a 100-megawatt fusion reactor in 2026, with an earlier 5-MW…